Acute myeloblastic leukaemia [AML] Clinical Trials

32 clinical trials for Acute myeloblastic leukaemia [AML] across international registries, including 13 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• INFORM Registry INdividualized Therapy FOr Relapsed Malignancies in Childhood — RECRUITING
• International multicenter, open-label clinical trial for the treatment of acute myeloid leukemia in children and adolescents — RECRUITING
• Identification of somatic and psychosocial late and long-term effects and associated risk factors in long-term survivors of acute myeloid leukemia - a foundation for evidence-based follow up care — RECRUITING
• Virtual reality-based meditation for enhancement of wellbeing, quality of life and patient satisfaction for in-patients undergoing chemotherapy — RECRUITING
• Register AML-BFM 2017 for the registration of acute myelogenous leukemia in children and adolescents — RECRUITING
• Clinical AML Registry and Biomaterial Database of the AML Cooparative Group (AML-CG) — RECRUITING
• Effects of endurance exercise on incidence and severity of cognitive impairments and other therapy-related side effects in leukemia and lymphoma patients undergoing high-dose chemotherapy. A randomized controlled trial. — RECRUITING
• Prognostic value and development of psycho-social factors and functional aspects in elderly patients with higher risk MDS and AMl. A multi-center observational study. — RECRUITING
• Phase I/II study of sensitization of non-M3 acute myeloid leukemia (AML) blasts to all-trans retinoic acid (ATRA) by epigenetic treatment with tranylcypromine (TCP), an inhibitor of the histone lysine demethylase 1 (LSD1) — RECRUITING
• “Incidence and outcome of invasive fungal infections in pediatric patients with hematological malignancies and/or undergoing allogeneic hematopoietic stem cell transplantation – a prospective analysis in three major pediatric cancer centers (IFI-PED Study)” — RECRUITING
• Health-related quality of life, mental distress und somatopsychic symptoms in adult patients with haematological neoplasms — RECRUITING
• A Study on the Epidemiology of Invasive Aspergillosis and Resistance Patterns of Aspergillus spp. — RECRUITING
• Randomized phase III study comparing the OSHO arm to the standard therapy arm of Geman AML Intergroup. Randomized comparison of Cytarabine and Mitoxantrone versus Fludarabine, Cytarabine, Mitoxantron and G-CSF treatment in patients not in remission after the first induction chemotherapy. Randomized comparison between one or two chemotherapy consolidation courses before autologous or allogeneic human stem cell transplantation in adult patients with AML under the age of 60 years. — RECRUITING
• Connection between birth mode and development of childhood leukemia — OTHER
• Quality of life and late effects in leukemia survivors — OTHER
• INTERNATIONAL MULTICENTER, OPEN-LABEL, PHASE 2 STUDY TO TREAT MOLECULAR RELAPSE OF PEDIATRIC ACUTE MYELOID LEUKEMIA WITH AZACITIDINE — OTHER
• Oncorelief - A Digital Guardian Angel Enhancing Cancer Patient Wellbeing and Health Status Improvement Following Treatment: A Pilot Study — OTHER
• A double-blind, placebo-controlled, randomized, multi-center phase II trial to assess the efficacy of Sorafenib-maintenance therapy in Flt3-ITD positive AML in complete hematological remission after allogenic stem cell transplantation — OTHER
• First in man study to evaluate the safety, tolerability and preliminary efficacy of the Fc-optimized FLT3 antibody FLYSYN for the treatment of acute myeloid leukemia patients with minimal residual disease — OTHER
• Thiotepa- Fludarabine- Treosulfan (TFT) conditioning for 2nd allogeneic PBSCT from unrelated donors in patients with AML relapsing from prior allogeneic HSCT — OTHER
• Phase 1/2 Trial to determine the Response Rate of Nivolumab in Acute Myeloid Leukemia (AML) relapse after Allogeneic Hematopoietic Cell Transplantation (allo-HCT) — OTHER
• An open-label, multicenter, study of INC424 monotherapy or in combination with azacitidine for patients with post-myeloproliferative disorders (MPD) – AML or with CMML — OTHER
• Response-Adapted Sequential Azacitidine And Chemotherapy in Patients > 60 Years Old With Newly Diagnosed AML Eligible for Chemotherapy and allogeneic hematopoietic cell transplantation: A Multicentre Phase I/II study of the East German Hematology and Oncology Study Group (OSHO) — OTHER
• Impact of intestinal microbiome on infections, course and outcome of haematological-oncological patients treated with chemotherapy — OTHER
• Clinical Trial for the treatment of acute myeloid leukaemia in children and adolescents — OTHER
• A multicenter Phase I/II trial investigating the safety and efficacy (CR rate and OS) of low dose AraC with Clofarabine in patients ≥60 years with AML not eligible for conventional Chemotherapy — OTHER
• Xploit Semantic Support for predictive modeling in Systems Medicine — OTHER
• A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated Acute Myeloid Leukemia (AML) with an IDH1 Mutation — OTHER
• Geriatric Assessment in patients older than 60 years with hematological malignancies undergoing allogeneic stem cell transplantation — OTHER
• Study of Low-Dose Cytarabine and Etoposide With or Without All-Trans Retinoic Acid in Older Patients Not Eligible for Intensive Chemotherapy With Acute Myeloid Leukemia and NPM1 Mutation — OTHER
• Tansfusion of granulocytes for patients with febrile neutropenia — OTHER
• Phase II study of low-dose intravenous decitabine in patients aged > 60 years with acute myeloid leukemia who are not eligible for standard induction chemotherapy — OTHER

Refine this search